Can you provide the average price target for ABBVIE INC stock?
39 analysts have analysed ABBV and the average price target is 255.68 USD. This implies a price increase of 22.47% is expected in the next year compared to the current price of 208.775.
NYSE:ABBV • US00287Y1091
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ABBVIE INC (ABBV).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-25 | RBC Capital | Initiate | Outperform |
| 2026-02-20 | Barclays | Initiate | Overweight |
| 2026-02-18 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2026-02-05 | UBS | Maintains | Neutral -> Neutral |
| 2026-02-05 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2026-02-05 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2026-01-27 | Citigroup | Maintains | Neutral -> Neutral |
| 2026-01-08 | Wolfe Research | Downgrade | Outperform -> Peer Perform |
| 2025-12-12 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-12-10 | HSBC | Upgrade | Hold -> Buy |
| 2025-11-07 | UBS | Maintains | Neutral -> Neutral |
| 2025-11-05 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2025-11-03 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-11-03 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-10-20 | Guggenheim | Maintains | Buy -> Buy |
| 2025-10-17 | Raymond James | Reiterate | Outperform -> Outperform |
| 2025-10-10 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-10-03 | B of A Securities | Maintains | Neutral -> Neutral |
| 2025-10-01 | HSBC | Downgrade | Buy -> Hold |
| 2025-09-22 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-09-17 | Berenberg | Upgrade | Hold -> Buy |
| 2025-09-16 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-09-15 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-09-12 | BMO Capital | Maintains | Outperform -> Outperform |
| 2025-09-12 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 54.318B -6.44% | 56.334B 3.71% | 61.16B 8.57% | 68.44B 11.90% | 74.004B 8.13% | 79.332B 7.20% | 83.389B 5.11% | 84.924B 1.84% | 86.73B 2.13% | 88.059B 1.53% | 88.73B 0.76% | |
| EBITDA YoY % growth | 25.251B -11.68% | 24.883B -1.46% | 29.077B 16.85% | 34.357B 18.16% | 37.907B 10.33% | 41.266B 8.86% | 40.135B -2.74% | 39.315B -2.04% | 38.815B -1.27% | 39.343B 1.36% | N/A | |
| EBIT YoY % growth | 16.553B -17.74% | 16.497B -0.34% | 20.938B 26.92% | 32.948B 57.36% | 36.62B 11.14% | 39.37B 7.51% | 43.079B 9.42% | 44.038B 2.23% | 45.267B 2.79% | 46.821B 3.43% | 47.339B 1.11% | |
| Operating Margin | 30.47% | 29.28% | 34.23% | 48.14% | 49.48% | 49.63% | 51.66% | 51.86% | 52.19% | 53.17% | 53.35% | |
| EPS YoY % growth | 11.11 -19.90% | 10.12 -8.91% | 10.00 -1.19% | 14.84 48.40% | 16.42 10.64% | 18.16 10.61% | 19.64 8.14% | 20.18 2.76% | 20.68 2.45% | 21.19 2.48% | 20.87 -1.52% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 3.08 25.08% | 3.85 29.79% | 3.77 102.75% | 3.94 45.50% |
| Revenue Q2Q % growth | 15.01B 12.49% | 17.148B 11.18% | 17.466B 10.71% | 18.298B 10.11% |
| EBITDA Q2Q % growth | 7.136B 18.54% | 8.881B -9.43% | 8.616B -25.62% | 9.012B -35.39% |
| EBIT Q2Q % growth | 6.939B 74.30% | 8.554B 49.62% | 8.677B 59.77% | 8.985B 54.67% |
All data in USD
39 analysts have analysed ABBV and the average price target is 255.68 USD. This implies a price increase of 22.47% is expected in the next year compared to the current price of 208.775.
ABBVIE INC (ABBV) will report earnings on 2026-04-23, before the market open.
The consensus EPS estimate for the next earnings of ABBVIE INC (ABBV) is 3.08 USD and the consensus revenue estimate is 15.01B USD.
The expected long term growth rate for ABBVIE INC (ABBV) is 8.46%.